X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (19) 19
humans (18) 18
aged (15) 15
male (15) 15
middle aged (15) 15
female (14) 14
double-blind method (13) 13
adult (11) 11
venous thromboembolism (11) 11
venous thromboembolism - drug therapy (11) 11
abridged index medicus (10) 10
hematology (10) 10
hemorrhage - chemically induced (10) 10
thromboembolism (10) 10
thrombosis (10) 10
anticoagulants (9) 9
anticoagulants - adverse effects (9) 9
medicine, general & internal (9) 9
warfarin (9) 9
anticoagulants - therapeutic use (8) 8
enoxaparin (8) 8
follow-up studies (8) 8
treatment outcome (8) 8
bleeding (7) 7
drug therapy (7) 7
life sciences (7) 7
pyridines - therapeutic use (7) 7
recurrence (7) 7
thiazoles - therapeutic use (7) 7
venous thrombosis (7) 7
warfarin - therapeutic use (7) 7
dosage and administration (6) 6
edoxaban (6) 6
enoxaparin - adverse effects (6) 6
hemorrhage (6) 6
kaplan-meier estimate (6) 6
molecular-weight heparin (6) 6
pulmonary embolism (6) 6
therapy (6) 6
veins & arteries (6) 6
acute disease (5) 5
embolisms (5) 5
factor xa inhibitors - therapeutic use (5) 5
human health and pathology (5) 5
peripheral vascular disease (5) 5
pulmonary embolism - drug therapy (5) 5
rivaroxaban (5) 5
warfarin - adverse effects (5) 5
atrial-fibrillation (4) 4
body weight (4) 4
cancer (4) 4
enoxaparin - therapeutic use (4) 4
patients (4) 4
prevention (4) 4
pyridines - adverse effects (4) 4
stroke, systemic or venous thromboembolism (4) 4
thiazoles - adverse effects (4) 4
venous thrombosis - drug therapy (4) 4
[ sdv.mhep ] life sciences [q-bio]/human health and pathology (3) 3
administration, oral (3) 3
anticoagulants - administration & dosage (3) 3
apixaban (3) 3
bone surgery (3) 3
care and treatment (3) 3
dabigatran (3) 3
deep-vein thrombosis (3) 3
direct oral anticoagulants (3) 3
drug administration schedule (3) 3
factor xa inhibitors (3) 3
fondaparinux (3) 3
health risk assessment (3) 3
hematology, oncology and palliative medicine (3) 3
heparin (3) 3
intention to treat analysis (3) 3
mesh : administration, oral (3) 3
mesh : aged (3) 3
mesh : anticoagulants (3) 3
mesh : enoxaparin (3) 3
mesh : female (3) 3
mesh : hemorrhage (3) 3
mesh : humans (3) 3
mesh : kaplan-meier estimate (3) 3
mesh : male (3) 3
mesh : middle aged (3) 3
neoplasms - complications (3) 3
prophylaxis (3) 3
pulmonary embolism - epidemiology (3) 3
pulmonary-embolism (3) 3
research (3) 3
risk factors (3) 3
venous thromboembolism - epidemiology (3) 3
vitamin k - antagonists & inhibitors (3) 3
active cancer (2) 2
acute pulmonary-embolism (2) 2
administration (2) 2
adolescent (2) 2
aged, 80 and over (2) 2
ambulatory care (2) 2
angiography (2) 2
arthroplasty (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 02/2018, Volume 378, Issue 7, pp. 615 - 624
Journal Article
Journal Article
Annals of internal medicine, ISSN 0003-4819, 2004, Volume 140, Issue 11, pp. 867 - 873
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 3, pp. 232 - 240
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 11/2019, Volume 17, Issue 11, pp. 1866 - 1874
Background Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence. Therefore, continued anticoagulant therapy beyond the... 
cancer | venous thromboembolism | edoxaban | hemorrhage | low‐molecular‐weight heparin | Anticoagulants | Thromboembolism | Bleeding | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2010, Volume 363, Issue 26, pp. 2499 - 2510
In this clinical trial, rivaroxaban, an oral factor Xa inhibitor, was effective in the initial and continued treatment of symptomatic venous thromboembolism;... 
MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | THERAPY | DISEASE | PREVENTION | DEEP-VEIN THROMBOSIS | IDRAPARINUX | Thiophenes - therapeutic use | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Warfarin - adverse effects | Male | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - drug therapy | Warfarin - therapeutic use | Rivaroxaban | Vitamin K - antagonists & inhibitors | Injections, Subcutaneous | Female | Morpholines - adverse effects | Morpholines - therapeutic use | Acute Disease | Double-Blind Method | Venous Thrombosis - drug therapy | Administration, Oral | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Acenocoumarol - adverse effects | Intention to Treat Analysis | Pulmonary Embolism - drug therapy | Acenocoumarol - therapeutic use | Aged | Hemorrhage - chemically induced | Anticoagulants (Medicine) | Thromboembolism | Drug therapy | Health aspects | Risk factors | Anticoagulants | Bone surgery | Veins & arteries | Venous Thrombosis | Factor Xa | Hemorrhage | Life Sciences | Venous Thromboembolism | Thiophenes | Acenocoumarol | Vitamin K | Warfarin | Enoxaparin | Morpholines | Human health and pathology | Pulmonary Embolism | MEDICIN OCH HÄLSOVETENSKAP | Oral | MEDICAL AND HEALTH SCIENCES | Administration | chemically induced | drug therapy | Subcutaneous | antagonists & inhibitors | Injections | adverse effects | therapeutic use
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 9, pp. 799 - 808
Journal Article
by Büller, Harry R and Prins, Martin H and Lensin, Anthonie W. A and Decousus, Hervé and Jacobson, Barry F and Minar, Erich and Chlumsky, Jaromir and Verhamme, Peter and Wells, Phil and Agnelli, Giancarlo and Cohen, Alexander and Berkowitz, Scott D and Bounameaux, Henri and Davidson, Bruce L and Misselwitz, Frank and Gallus, Alex S and Raskob, Gary E and Schellong, Sebastian and Segers, Annelise and Berkowitz, Scott and Gallus, Alexander and Lensing, Anthonie W. A and Haskell, Lloyd and Raskob, Gary and Bauersachs, Rupert and van Bellen, Bonno and Boda, Zoltán and Borris, Lars and Brenner, Benjamin and Brighton, Tim and Davidson, Bruce and Decousus, Herve and Eriksson, Henry and Jacobson, Barry and Kakkar, Ajay and Kwong, Yok-Lam and Lee, Lai Heng and Meijer, Karina and van der Meer, Jan and Monreal, Manuel and Piovella, Franco and Sandset, Per Morten and Smith, Mark and Tomkowski, Witold and Wang, Yuqi and Brandjes, Dees and Mac Gillavry, Melvin and Otten, Hans-Martin and Carlsson, Anders and Laporte, Silvy and Schulman, Sam and Gent, Michael and Turpie, Alexander and Martinelli, Ida and Lensing, Anthonie W and Muhlhofer, Eva and Tewes, Miriam and Trajanovic, Mila and Muller, Karin and Kim, Calvin and Gebel, Martin and Benson, Alice and Pap, Akos Ferenc and Goie, Juliette and Horvat-Broecker, Anea and Spadari, Giovanni and Peters-Wulf, Cornelia and Roig, J and Baker, R and Bianchi, A and Blombery, P and Brighton, T and Campbell, P and Carroll, P and Geraghty, R and Chong, B and Ramanathan, S and Archis, C and Coughlin, P and Salem, H and Crispin, P and Dean, M and Soni, R and Denaro, C and Kubler, P and Coghlan, D and Gallus, A and Gan, T. Eng and Tran, H and Coleman, C and Jackson, D and Khalafallah, A and Leahy, M and Leyden, M and Leyden, D and Sturtz, C and McCann, A and Gibbs, H and McRae, S and Richards, B and ... and The EINSTEIN–PE Investigators and EINSTEIN-PE Investigators and EINSTEIN–PE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 04/2012, Volume 366, Issue 14, pp. 1287 - 1297
Journal Article